Pricing Log in Create free account
Friday 6 November 2026 Export DNTH’s income statement to Excel — free account

Dianthus Therapeutics, Inc.

DNTH Healthcare Biotechnology

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.

Revenue
+205.6%
EPS
+16.1%
Free cash flow
−65.9%

Quarter to September 2026, against a year earlier

86.43 3.42 +4.12%
Market cap
$4.6B
P/E
0.0×
Fwd P/E
−21.5×
Dividend yield
—
F-score
2/9
Altman Z
24.31
Beneish M
−4.75
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 63.82
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — 6 1 1 2 1 5 2 — —
Insider Ownership 18.89%

Capital & Financial Ratios $m

Size
Market Cap 4,640.00
Revenue ttm 2.72
Net income ttm (202.12)
Free cash flow ttm (175.85)
Net debt Q (837.78)
Valuation
P/E 0.00
Forward P/E (21.50) (negative: loss-making)
Price / sales 1,823.40 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.99
Financial health
Current ratio Q 30.02 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +205.56% (above 0%: growing)
Operating income growth Q −45.14% (below 0%: shrinking)
EPS, this year +15.41% (at or above 15%: strong)
EPS, next year A −23.53% (below 0%: weak)
Revenue, next year A −5.75% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −8.74% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1,515×, against a ten-year median of 100×; over the ten years it ranged from −26.8× in 2024 to 2,681× in 2026.
P/S against its own 10 years 84.58%
10-year low 10-year high
P/B against its own 10 years 90.29%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 174 275 404 838
Receivables 0 1 0 1
Inventory — — — —
Other — — — —
177 281 409 856
2023 2024 2025 Q'26
Payables 3 5 10 5
ST’ Debt — — — —
Other — — — —
10 18 31 29

Compound Annual Growth %

10y 5y 3y
Sales — — (31.80%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 27.95% 88.51%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.00 Actual −0.81

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.98 −1.43 Miss by 0.45
Q1 FY26 −1.17 −0.85 Beat by 0.32
Q2 FY26 −0.93 −0.90 Beat by 0.03
Q3 FY26 −1.00 −0.81 Beat by 0.19
Q4 FY26 −1.06 — Reports 8 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.85) (0.90) (0.81) — —
’25 (0.82) (0.88) (0.97) (1.43) (4.20)
’24 (0.54) (0.51) (0.74) (0.81) (2.55)
’23 (8.10) (12.73) (3.78) (0.71) (8.45)
’22 (6.24) (4.64) (8.90) (12.74) (32.58)
’21 (5.76) (5.12) (4.80) (5.28) (20.64)
’20 (8.16) (7.68) (5.92) (6.08) (27.36)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 1 1 — —
’25 1 0 0 0 2
’24 1 2 2 1 6
’23 0 1 1 0 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (29) (49) (50) — —
’25 (28) (24) (31) (47) (129)
’24 (15) (15) (21) (27) (78)
’23 (10) (5) (10) (12) (37)
’22 (20) (17) 16 (9) (29)
’21 (17) (13) (14) (16) (60)
’20 (17) (19) (14) (14) (64)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (29) (49) (51) — —
’25 (28) (24) (31) (47) (129)
’24 (15) (15) (21) (27) (78)
’23 (10) (5) (10) (12) (37)
’22 (20) (17) 16 (9) (29)
’21 (17) (13) (15) (16) (61)
’20 (17) (19) (14) (14) (64)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — 6 3 6 2 3 (31.8%) 2 2 9 +63.2%
Gross margin, % 0.00 0.00 0.00 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 +100.0 pt
EBT (9) (35) (58) (77) (75) (71) (28) (44) (85) (162) (202) +37.2%
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 (443.76) (1,541.22) (1,362.77) (7,973.33) (7,436.50) (7,973.3) pt
Net income (9) (35) (58) (77) (75) (71) (28) (44) (85) (162) (202) +37.2%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 7.34 0.55 0.19 0.05 0.05 n/m
Earnings (1,009.92) (305.81) (50.08) (33.12) (27.36) (20.64) (32.58) (8.45) (2.55) (4.20) (3.99) (45.6%)
Cash flow (702.04) (191.76) (36.44) (24.68) (23.32) (17.33) (33.26) (7.15) (2.35) (3.34) (3.05) (44.8%)
Capex (14.95) (18.94) (6.66) (1.32) (0.15) (0.37) (0.16) (0.02) 0.00 (0.01) (0.01) (58.5%)
Free cash flow (716.99) (210.70) (43.11) (26.01) (23.47) (17.70) (33.42) (7.17) (2.35) (3.35) (3.07) (44.9%)
Book value (954.19) (362.77) 126.73 61.03 52.42 50.28 84.27 32.77 10.58 12.78 21.65 n/m
Shares, m 0 0 1 2 3 3 1 5 33 39 50 +152.4%
Valuation, ×
Valuation, × P/E — — — — — — 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — — — — 0.00 20.88 116.48 781.65 1,823.40 229.8
P/B — — — — — — 0.00 0.35 2.06 3.23 3.99 1.4
EV/Sales — — — — — — 0.00 (40.59) 72.33 583.07 1,515.16 153.7
EV/FCF — — — — — — 2.39 3.10 (5.76) (9.18) (23.42) (2.4)
Cash, $m
Cash, $m Operating cash flow (7) (22) (42) (57) (64) (60) (29) (37) (78) (129) (175) +39.3%
Capex 0 (2) (8) (3) 0 (1) 0 0 0 0 (1) +4.9%
Free cash flow (7) (24) (50) (60) (64) (61) (29) (37) (78) (129) (176) +39.0%
Balance, $m
Balance, $m Working capital 9 48 135 136 140 170 74 168 262 379 828 +52.4%
Net debt (5) (52) (143) (146) (149) (177) (75) (174) (275) (404) (838) +64.7%
Shareholders’ equity (9) (42) 146 141 144 173 74 169 352 493 1,241 n/m
Returns, %
Returns, % ROA (29.59) (107.92) (54.40) (48.16) (46.38) (40.47) (20.86) (33.18) (30.71) (35.88) (21.81) (6.3) pt
ROIC 0.00 0.00 (1,217.57) 0.00 0.00 0.00 0.00 0.00 (82.43) (124.80) (36.55) (124.8) pt
ROE 38.18 139.26 (111.28) (53.53) (52.57) (44.94) (44.39) (69.97) (32.60) (38.38) (22.61) (76.6) pt
People
People Employees — 48 59 72 69 75 67 53 78 92 — +8.5%
Revenue/emp, $m — 0.00 0.00 0.00 0.00 0.00 0.10 0.05 0.08 0.02 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Dianthus Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MANE Veradermics Incorporated $5.4B — (loss-making) — — n/m −8.81% (below 0%: shrinking) — 0.00% Compare
COGT Cogent Biosciences, Inc. $5.1B — (loss-making) — (loss-making) −69.41% (below 0%: shrinking) n/m −42.01% (below 0%: shrinking) 0.00% 0.00% Compare
CRSP CRISPR Therapeutics AG $4.7B — (loss-making) — (loss-making) +1,325.08% (above 0%: growing) n/m −6.36% (below 0%: shrinking) 100.00% (1,026.48%) Compare
TVTX Travere Therapeutics, Inc. $4.7B — (loss-making) — (loss-making) +36.22% (above 0%: growing) n/m +6,379.75% (above 0%: growing) 98.72% (30.33%) Compare
DNTH Dianthus Therapeutics, Inc. $4.6B — (loss-making) — (loss-making) +205.56% (above 0%: growing) n/m −65.91% (below 0%: shrinking) 100.00% (4,832.40%)
ERAS Erasca, Inc. $4.6B — (loss-making) — — n/m −4.67% (below 0%: shrinking) 0.00% 0.00% Compare
LEGN Legend Biotech Corporation Sponsored ADR $4.4B — (loss-making) — (loss-making) +51.90% (above 0%: growing) n/m −26.79% (below 0%: shrinking) 64.54% 14.37% Compare
EWTX Edgewise Therapeutics, Inc. $4.2B 4.9× — — n/m −30.24% (below 0%: shrinking) 0.00% 0.00% Compare
DFTX Definium Therapeutics, Inc. $4.1B — (loss-making) — — n/m −78.31% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $4.7B — — +44.06% — −17.80% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 9 April 2026

Ownership

Directors and executive officers, together 3.02%
FMR LLC 13.05%
Entities affiliated with Wellington Management Group LLP 5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Dianthus Therapeutics, Inc. (DNTH) Latest News

4 Nov

Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · Zacks

20 Oct

Impact 3 · · Simply Wall St.

29 Sep

Impact 3 · · GlobeNewswire

24 Sep

Impact 4 · · Simply Wall St.

23 Sep

Impact 3 · · Simply Wall St.

5 Sep

Impact 3 ·

4 Aug

Impact 4 ·
Impact 3 ·

29 Jun

Impact 4 ·

17 Jun

Impact 3 ·

15 Jun

Impact 3 ·

12 Jun

Impact 4 · · Stocktwits

9 Jun

Impact 4 · · Simply Wall St.

5 Jun

Impact 3 · · Insider Monkey

18 May

Impact 4 · · Simply Wall St.

17 May

Impact 3 · · The Motley Fool

5 May

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

27 Apr

Impact 4 · · Simply Wall St.

23 Apr

Impact 4 · · Insider Monkey

3 Apr

Impact 4 · · Simply Wall St.

18 Mar

Impact 5 · · The Motley Fool
Impact 3 · · Insider Monkey

15 Mar

Impact 4 · · MarketBeat

12 Mar

Impact 5 · · GlobeNewswire
Impact 4 · · Simply Wall St.

10 Mar

Impact 4 · · GlobeNewswire

9 Mar

Impact 4 · · GlobeNewswire

DNTH metrics, ten years each

stockrow.com/DNTH · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com